Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has shared an update.
On July 22, 2025, NeOnc Technologies Holdings, Inc. announced the execution of a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, marking a significant milestone in its $50 million strategic partnership with Quazar Investment. This agreement, covering the UAE and the wider GCC and MENA region for NEO100 and NEO212, is part of NeOnc’s broader strategy to expand its market presence and enhance capital market strategies. The partnership aims to transform NeOnc from a clinical-stage biotech to a global brain cancer platform, with Quazar leading a capital formation round and allocating funds for stock acquisition and clinical trials in the MENA region.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics. The company aims to overcome the challenges of the blood-brain barrier with its NEO™ drug development platform, which has produced novel drug candidates and delivery methods. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II clinical trials and have FDA Fast-Track and IND status. The company holds an extensive patent portfolio licensed from the University of Southern California.
Average Trading Volume: 138,201
For an in-depth examination of NTHI stock, go to TipRanks’ Overview page.